Regeneron in $400M senior note deal
This article was originally published in Scrip
Regeneron Pharmaceuticals said it has priced a $400 million offering involving the sale of $1.875% senior convertible notes due 1 October 2016. A At the close, the company expects net proceeds of about $391.3 million after expenses. The notes have an initial conversion price of $84.02 per share, which is about a 30% premium to Regeneron's close of $64.63 on 17 October, the day before the deal was announced.